Long-Term Outcomes Following Liver Transplantation for Hepatic Hemangioendothelioma: The UNOS Experience from 1987 to 2005

Rodriguez, Joel A.; Becker, Natasha S.; O’Mahony, Christine A.; Goss, John A.; Aloia, Thomas A.

doi:10.1007/s11605-007-0247-3

Cited by 109 publications

(105 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, TACE is recommended if the lesions are unresectable. According to previous findings [3,[8][9][10][11][12][13], LT has favorable outcomes in HEHE patients, yet its indications are not well defined. Additional investigations in larger studies are needed to compare further the differences between LT and other treatments.…”

Section: Discussionmentioning

confidence: 99%

Clinical Experience with Primary Hepatic Epithelioid Hemangioendothelioma: Retrospective Study of 33 Patients

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Experience with Primary Hepatic Epithelioid Hemangioendothelioma: Retrospective Study of 33 Patients

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Three large series (>50 patients) of LT for hepatic epithelioid hemangioendothelioma (HEHE) reported satisfactory 5-y survival rates ranging from 55-83%. [67][68][69] All of them have proposed an aggressive attitude toward unresectable HEHE even in patients with lymph node involvement or extrahepatic disease because both factors did not significantly affect survival when appropriate multimodal treatments were employed. Pretransplant medical condition and vascular invasion have been described as poor prognostic predictors.…”

Section: -52mentioning

confidence: 99%

“…Pretransplant medical condition and vascular invasion have been described as poor prognostic predictors. 68,69 The use of anti-vascular endothelial cell growth factor agents is expected to further improve outcomes. 68,70 Recently, Grotz et al stated that patients with tumor size ≤ 10 cm, number up to 10, and extent of hepatic involvement up to 4 segments, are candidates for liver resection rather than LT and further investigations are warranted to clearly define the role of each surgical treatment.…”

Section: -52mentioning

confidence: 99%

Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine

et al. 2014

View full text Add to dashboard Cite

“…17 Its clinical presentation is nonspecific and includes abdominal pain, hepatomegaly, and fatigue. 18,19 The clinical course of hepatic epithelioid hemangioendothelioma varies between almost benign behavior, like hemangioma, to rapid progress, like angiosarcoma. 20 Liver transplant remains the only potentially curative approach for unresectable hepatic epithelioid hemangioendothelioma with or without extrahepatic tumor manifestation.…”

Section: Introductionmentioning

confidence: 99%

Untitled

Haberal

2017

Exp Clin Transplant

View full text Add to dashboard Cite

Liver transplant is now an acceptable and effective treatment for specific nonhepatocellular malignancies. Worldwide, hilar cholangiocarcinoma accounts for 3% of all primary gastrointestinal malignancies and for 10% of primary hepatobiliary malignancies. For patients who have early-stage, unresectable cholangiocarcinoma, liver transplant preceded by neoadjuvant radiotherapy can result in tumor-free margins, accomplish a radical resection, and treat the underlying primary sclerosing cholangitis when present. Hepatic epithelioid hemangioendothelioma is a rare tumor of vascular origin with a variable malignant potential. Excellent results have been reported with liver transplant for patients with unresectable hepatic epithelioid hemangioendothelioma, with 1-year and 10-year survival rates of 96% and 72%. Hepatoblastoma is the most common primary hepatic malignancy in children. The long-term survival rate after transplant ranges from 66% to 77% in patients with unresectable tumors and good response to chemotherapy. Metastatic liver disease is not an indication for liver transplant, with the exception of cases in which the primary tumor is a neuroendocrine tumor. Indication for liver transplant for hepatic metastasis from neuroendocrine tumors is mainly for patients with unresectable tumors and for palliation of medically uncontrollable symptoms. Posttransplant survival in those patients with low tumor activity index is excellent, despite recurrence of the tumor. Some recent data on liver transplant for unresectable hepatic metastases from colorectal cancer have reported limited survival benefits compared with previous reports. However, due to the high rate of tumor recurrence in a very short time after liver transplant, especially in the era of organ shortage, this indication has not been favored by the transplant community. The indications for liver transplant for nonhepatocellular carcinoma malignancy and its limitations have evolved dramatically over the past decades and will continue to be redefined through future research and investigations.

show abstract

Long-Term Outcomes Following Liver Transplantation for Hepatic Hemangioendothelioma: The UNOS Experience from 1987 to 2005

Abstract: These data indicate that survivals after transplantation for HEH are favorable. Given the propensity for recurrence after resection, these data support consideration of liver transplantation for all patients with significant intrahepatic tumor burden.

Cited by 109 publications

References 15 publications

Clinical Experience with Primary Hepatic Epithelioid Hemangioendothelioma: Retrospective Study of 33 Patients

Clinical Experience with Primary Hepatic Epithelioid Hemangioendothelioma: Retrospective Study of 33 Patients

Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine

Untitled

Contact Info

Product

Resources

About